The heart of this collaboration lies in the deployment of GemPharmatech’s NeoMab® platform, a next-generation transgenic mouse model engineered for the swift and efficient identification of fully human therapeutic antibodies. The NeoMab® model has revolutionized antibody discovery by carrying an extensive repertoire of human immunoglobulin variable genes in a BALB/c mouse genetic background, eliminating the traditionally laborious step of sequence humanization. This innovation dramatically reduces development timelines and minimizes immunogenicity concerns that have historically challenged antibody therapeutics.

Memorial Sloan Kettering researchers will tap into NeoMab®’s sophisticated design to generate diverse arrays of high-affinity, fully human antibodies. Unlike previous models, which required extensive post-discovery modifications to humanize antibodies derived from murine sequences, NeoMab® mice produce antibodies with inherently human variable regions. This capacity aligns with current demands for biomarkers and immunotherapies that avoid adverse immune responses, accelerating translation from bench to bedside.

Dr. Xiang Gao, founder of GemPharmatech, emphasized the transformational potential of this alliance, remarking that their mission is deeply rooted in enabling pioneering biomedical research via innovative mouse models and technologies. He expressed enthusiasm about melding MSK’s scientific excellence with NeoMab®’s capabilities to accelerate discovery pipelines for novel cancer therapeutics, potentially altering the landscape of oncology drug development.

The NeoMab® platform’s unique genetic engineering involves the humanization of immunoglobulin loci, introducing the full human heavy and kappa light chain variable region gene repertoires along with relevant regulatory elements. Embedded in a BALB/c background—a well-characterized murine strain—the platform offers researchers a robust and reliable system that faithfully recapitulates human antibody diversity and affinity maturation processes, facilitating the generation of therapeutic candidates with optimal specificity and potency.

Memorial Sloan Kettering’s expertise in oncology research, combined with access to such a powerful antibody discovery platform, promises to accelerate identification of antibodies against high-value and challenging cancer targets. This project is poised to hone therapeutic antibodies that can disrupt tumorigenic pathways, modulate immune checkpoints, or enhance immune cell infiltration within the tumor microenvironment—areas of investigation paramount to advancing precision oncology.

Beyond oncology, the collaboration exemplifies a broader shift in preclinical drug discovery, where sophisticated genetically engineered models supplant older, less predictive systems. The ability to generate fully human antibodies in an immunologically competent host reduces the risk of immunogenicity upon clinical application, thereby improving safety profiles and success rates in later-stage clinical trials.

Dr. Brandy Wilkinson, CEO of GemPharmatech, highlighted the strategic importance of this partnership in fulfilling the company’s mission to furnish the global scientific community with state-of-the-art tools that accelerate drug innovation. She underlined the honor and responsibility of supporting MSK’s trailblazing oncology programs, reinforcing that the NeoMab® platform will be instrumental in expediting antibody programs that are poised to transform patient care worldwide.

GemPharmatech’s extensive portfolio, anchored by the world’s largest library of genetically engineered mouse models (GEMMs), grants unparalleled versatility to researchers. With access to over 25,000 mouse strains—including knockout, conditional knockout, humanized, and immunodeficient variants—the company has established itself as a vital partner in the discovery and validation of therapeutic candidates across multiple complex disease areas.

Innovations like the NeoMab® model illustrate the powerful synergy between genetic engineering and immunology, facilitating breakthroughs not merely in antibody discovery but also in understanding immune regulation, antigen presentation, and tumor immune evasion. These insights hold transformative potential for designing combination therapies that leverage both immunomodulation and direct tumor targeting.

As the collaboration advances, the scientific community will be keenly observing the generation, characterization, and preclinical efficacy of novel fully human antibodies emerging from this alliance. Success in this domain promises not only to shorten discovery timelines but also to elevate the quality and manufacturability of antibody drugs entering clinical evaluation, setting new standards for therapeutic innovation.

Ultimately, this partnership between GemPharmatech and Memorial Sloan Kettering exemplifies the convergence of technological innovation and rigorous scientific expertise in pursuit of better cancer treatments. By harnessing next-generation genetically engineered models like NeoMab®, the collaboration stands as a beacon of hope for patients and researchers alike, accelerating the advent of transformative antibody-based therapeutics in oncology.

Subject of Research: Not applicable
Article Title: [Information not provided]
News Publication Date: [Information not provided]
Web References: https://en.gempharmatech.com/
Keywords: Oncology, Cancer research

Seeking to overcome these hurdles, researchers at the University of California, Davis, have spearheaded the development of an innovative nanoparticle platform that holds great promise in revolutionizing bladder cancer therapy. This multidisciplinary team, led by Professors Tzu-Yin Lin, Yuanpei Li, and Jinhwan Kim, has harnessed the power of phototherapy—specifically photodynamic therapy (PDT) and photothermal therapy (PTT)—and combined it with advanced imaging techniques. Their creation, known as pyropheophorbide a–bisaminoquinoline conjugate lipid nanoparticles (PPBC LNPs), integrates therapeutic and diagnostic functions, enabling real-time visualization of drug distribution and treatment response.

Phototherapy has emerged as a compelling alternative in oncology, particularly because of its ability to selectively induce cancer cell death through light-activated mechanisms while minimizing damage to surrounding healthy tissues. However, conventional phototherapy approaches are often constrained by the oxygen dependency of PDT, limited penetration depth of therapeutic agents, and challenges related to precise monitoring of therapeutic delivery. The PPBC LNPs are ingeniously designed to circumvent these limitations by combining potent photodynamic and photothermal effects within a single nanoscale system, while simultaneously providing bimodal imaging capabilities to guide and optimize treatment.

The formulation of PPBC LNPs employs a microfluidic synthesis platform, which allows for highly controlled assembly of nanoparticles leading to uniform size distribution and scalability for mass production. Each nanoparticle averages 107 nanometers in diameter with a narrow polydispersity index, indicating consistent particle size essential for predictable pharmacokinetics and biodistribution. Their lipid-based design ensures excellent biocompatibility and stability, traits that are crucial for clinical translation, including prolonged circulation time and easy storage.

Functionally, these nanoparticles are capable of generating reactive oxygen species (ROS) upon light irradiation, a hallmark of photodynamic therapy that facilitates oxidative damage to cancer cells. Concurrently, the nanoparticles exhibit efficient photothermal conversion, generating localized hyperthermia with a reported conversion efficiency of 32.7%, sufficient to cause thermal ablation of tumor tissues. This dual therapeutic capability ensures that even hypoxic tumor regions, typically resistant to oxygen-dependent PDT, can be effectively targeted via photothermal mechanisms.

One of the most exciting features of PPBC LNPs is their ability to facilitate bimodal imaging using photoacoustic (PA) and fluorescence (FL) modalities. The nanoparticles’ strong near-infrared absorption properties enable deep tissue penetration for PA imaging, which captures ultrasonic signals generated by light absorption. This provides high-resolution imaging of the tumor microenvironment non-invasively. Complementary fluorescence imaging offers sensitive detection of nanoparticle accumulation with real-time feedback on therapy localization. Together, these imaging techniques present an unprecedented level of precision for tracking drug biodistribution and dynamically assessing therapeutic efficacy.

Preclinical studies in murine models of bladder cancer have demonstrated the profound potential of this theranostic platform. In both subcutaneous and orthotopic tumor models, administration of PPBC LNPs followed by laser irradiation led to significant tumor growth inhibition. Remarkably, several treated tumors exhibited complete ablation after only two treatment cycles. This outcome underscores the synergistic effect of combined PDT and PTT, amplified further by the nanoparticles’ ability to impair autophagy pathways in cancer cells—a biological process often implicated in therapeutic resistance.

Importantly, safety evaluations revealed that the therapy was well-tolerated in animal models. The treated subjects maintained stable body weight and did not present with histopathological abnormalities in major organs, highlighting the biocompatibility and minimized systemic toxicity of the lipid nanoparticle formulation. This safety profile is essential for the design of next-generation cancer therapies and further reinforces the potential clinical utility of PPBC LNPs.

Beyond the therapeutic advantages, the use of integrated dual imaging modalities allows clinicians to optimize treatment schedules by identifying the most effective time points for light irradiation based on nanoparticle tumor accumulation and retention. Imaging signals demonstrated prolonged retention of the nanoparticles in tumors for up to six days, suggesting sustained therapeutic availability and reduced need for frequent dosing. This real-time monitoring capability offers a dynamic window into the tumor’s response, allowing treatments to be customized for individual patients.

Looking ahead, the research team envisions further refinement and clinical translation of this technology. The scalable microfluidic synthesis method supports consistent production of these multifunctional nanoparticles, a critical step in meeting regulatory demands. Planned preclinical studies in larger animal models aim to comprehensively evaluate efficacy and safety under conditions that closely mimic human bladder cancer.

Additionally, the integration of catheter-based and endoscopic photoacoustic probes represents a promising direction to enhance imaging resolution and accessibility directly within the bladder. This approach could facilitate precise diagnosis, monitoring, and guided phototherapy in clinical settings, directly addressing current limitations in bladder cancer management and bridging the gap toward personalized medicine.

The development of PPBC LNPs exemplifies the convergence of nanotechnology, imaging science, and oncology, potentially setting a new standard for cancer theranostics. By combining selective, localized treatment with highly sensitive and deep-penetrating imaging, this platform could dramatically improve treatment outcomes and quality of life for patients battling bladder cancer. As the team at UC Davis continues to push the envelope, the implications of their work extend beyond bladder cancer, illuminating pathways for similar innovations across multiple disease types.

This breakthrough underscores how nanomedicine can transform cancer therapy by achieving the delicate balance between therapeutic potency and safety while providing clinicians with essential tools to tailor treatment regimens. The integration of biologically active nanoparticles with real-time imaging is a vivid example of precision medicine moving from concept to reality, promising to change the landscape of cancer care profoundly in the coming years.

Stay tuned as further research unveils the full clinical potential of these multifunctional lipid nanoparticles and explores their applicability in broader oncologic contexts. The marriage of clinically relevant drug delivery, phototherapy, and multimodal imaging stands as a beacon of hope, demonstrating the power of multidisciplinary approaches in overcoming one of medicine’s most enduring challenges.

Subject of Research: Multifunctional nanoparticles for image-guided phototherapy in bladder cancer treatment

Article Title: Multifunctional and Scalable Nanoparticles for Bimodal Image-Guided Phototherapy in Bladder Cancer Treatment

News Publication Date: 18-Apr-2025

Web References:
https://doi.org/10.1007/s40820-025-01717-0

Image Credits: Menghuan Tang, Sohaib Mahri, Ya-Ping Shiau, Tasneem Mukarrama, Rodolfo Villa, Qiufang Zong, Kelsey Jane Racacho, Yangxiong Li, Yunyoung Lee, Yanyu Huang, Zhaoqing Cong, Jinhwan Kim, Yuanpei Li, Tzu-Yin Lin.

Keywords: Cancer, bladder cancer, nanoparticle, photodynamic therapy, photothermal therapy, bimodal imaging, photoacoustic imaging, fluorescence imaging, nanomedicine, drug delivery, theranostics